Edgewise Therapeutics (EWTX) risk factors, FY2025 10-K

Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History

1. 01We have not generated any revenue to date, have incurred significant net losses since our inception, and expect to continue to incur significant net losses for the foreseeable future27% rewritten
2. 02Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates, if approved
3. 03We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts
4. 04A change in the outcome of any of these or other factors with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate
5. 05Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates
6. 06Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates39% rewritten
7. 07Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited28% rewritten
8. 08Changes in tax laws could have a material adverse effect on our business, cash flow, results of operations or financial conditions81% rewritten
9. 09Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay key vendors and others
10. 10Our operations and financial results could be adversely impacted by public health pandemics, such as COVID-19 and other related outbreaks in the United States and the rest of the world
11. 11Any continued and prolonged public health crisis could have a material negative impact on our business, financial condition and operating results30% rewritten

Risks Related to the Discovery, Development and Commercialization of Our Product Candidates

1. 12We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500. If we are unable to complete further development of, obtain approval for and commercialize sevasemten or EDG-7500 for one or more indications in a timely manner, our business will be harmed62% rewritten
2. 13have chosen. As a result, we cannot assure you that any clinical trials that we conduct will demonstrate consistent or adequate efficacy and safety to support marketing approvalNew
3. 14The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities
4. 15If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented22% rewritten
5. 16We have limited resources and are currently focusing the majority of our efforts on developing sevasemten and EDG-7500 for particular indications. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable
6. 17We face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted42% rewritten
7. 18Interim, topline and preliminary data from our clinical trials that we announce or publish may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data22% rewritten
8. 19We may not be successful in our efforts to develop a proprietary drug discovery platform to build a pipeline of product candidates
9. 20We may develop sevasemten and potentially other programs in combination with other therapies, which would expose us to additional risks
10. 21Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
11. 22Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success
12. 23If any of our product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted31% rewritten
13. 24We may not be successful in augmenting our product pipeline through acquisitions and in-licenses
14. 25Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations

Risks Related to Regulatory Approval and Other Legal Compliance Matters

1. 26The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction
2. 27Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions59% rewritten
3. 28changes in healthcare regulation could be time-intensive and expensive, resulting in a material adverse effect on our businessNew
4. 29The regulatory approval processes for product candidates that target rare diseases, including Duchenne, Becker and LGMD are uncertain
5. 30Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight
6. 31We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products
7. 32We may face difficulties from changes to current regulations and future legislation25% rewritten
8. 33Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
9. 34If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business41% rewritten
10. 35employees, agents, representatives, business partners and third-party intermediaries, or those of our affiliates, will comply with applicable laws and regulations, for which we may be ultimately held responsibleNew

Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business

1. 36Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees68% rewritten
2. 37employees. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention effortsNew
3. 38If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval
4. 39In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth23% rewritten
5. 40Our operations are vulnerable to interruption by fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm our business
6. 41Our business may become subject to economic, political, regulatory and other risks associated with international operations directly or indirectly. A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business46% rewritten
7. 42Inflation in the global economy could negatively impact our business and results of operations

Risks Related to Our Intellectual Property

1. 43Our success depends on our ability to protect our intellectual property and our proprietary technologies24% rewritten
2. 44patent authorities to fulfill their functions and could greatly impact our ability to timely and adequately prosecute or maintain our patent applications, and our ability to timely and adequately maintain, enforce, or defend our issued patentsNew
3. 45If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected
4. 46Intellectual property rights do not necessarily address all potential threats to our competitive advantage
5. 47Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts49% rewritten
6. 48are difficult to enforce and that we would have valid defenses to these claims of patent infringement, we cannot be certain that we would prevail in any dispute and we cannot be certain how an adverse determination would affect our businessNew
7. 49negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technologyNew
8. 50We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses
9. 51We may be involved in lawsuits to protect or enforce our patents or any licensor’s patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or any licensor’s patents could be found invalid or unenforceable if challenged in court
10. 52In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent applications of any licensor is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates
11. 53In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology
12. 54Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline
13. 55Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
14. 56Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
15. 57We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
16. 58Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
17. 59If we do not obtain patent term extension for our product candidates, our business may be materially harmed26% rewritten
18. 60We may not be able to protect our intellectual property rights throughout the world
19. 61Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
20. 62If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
21. 63If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
22. 64We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets40% rewritten
23. 65in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employeesNew
24. 66We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers
25. 67Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others
26. 68If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with any licensors, we could lose license rights that are important to our business
27. 69The patent protection and patent prosecution for some of our product candidates may be dependent on third parties76% rewritten

Risks Related to Our Dependence on Third Parties

1. 70We rely, and expect to continue to rely, on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies, which may harm our business
2. 71Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
3. 72If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
4. 73If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans81% rewritten
5. 74We may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates

Risks Related to the Securities Markets and Ownership of Our Common Stock

1. 75An active, liquid and orderly trading market may not continue to be developed or sustained for our common stock and as a result it may be difficult for you to sell your shares of our common stock
2. 76The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment
3. 77Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance
4. 78Our affiliated principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
5. 79Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall21% rewritten
6. 80If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
7. 81We incur significantly increased costs and devote substantial management time as a result of operating as a public company. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
8. 82Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
9. 83We may be subject to securities litigation, which is expensive and could divert management attention
10. 84We do not intend to pay dividends on our common stock in the foreseeable future, so any returns will be limited to the value of our common stock
11. 85Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock
12. 86Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act